Projects per year
Abstract
Programmable DNA endonucleases derived from bacterial genetic defense systems, exemplified by CRISPR-Cas9, have made it significantly easier to perform genomic modifications in living cells. However, unprogrammed, off-target modifications can have serious consequences, as they often disrupt the function or regulation of non-targeted genes and compromise the safety of therapeutic gene editing applications. High-fidelity mutants of Cas9 have been established to enable more accurate gene editing, but these are typically less efficient. Here, we merge the strengths of high-fidelity Cas9 and hyperactive Cas9 variants to provide an enzyme, which we dub HyperDriveCas9, that yields the desirable properties of both parents. HyperDriveCas9 functions efficiently in mammalian cells and introduces insertion and deletion mutations into targeted genomic regions while maintaining a favorable off-target profile. HyperDriveCas9 is a precise and efficient tool for gene editing applications in science and medicine.
Original language | English |
---|---|
Article number | 100756 |
Number of pages | 13 |
Journal | Cell Reports Methods |
Volume | 4 |
Issue number | 4 |
DOIs | |
Publication status | Published - 22 Apr 2024 |
Fingerprint
Dive into the research topics of 'Mutational rescue of the activity of high-fidelity Cas9 enzymes'. Together they form a unique fingerprint.-
ARC Centre of Excellence in Synthetic Biology
Paulsen, I. (Investigator 01), Filipovska, A. (Investigator 02), Nielsen, L. (Investigator 03), Parker, R. (Investigator 04), Neilan, B. (Investigator 05), Alexandrov, K. (Investigator 06), Sherman, B. (Investigator 07) & Jackson, C. (Investigator 08)
ARC Australian Research Council
1/01/20 → 8/11/27
Project: Research
-
Designing new therapeutics using medical synthetic biology
Rackham, O. (Investigator 01)
NHMRC National Health and Medical Research Council
1/01/19 → 9/10/20
Project: Research